A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ�38518168 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy
Read time: 1 mins
Last updated:4th Sep 2012
The primary objective is to assess the efficacy (as measured by the reduction of the signs and symptoms of RA) of JNJ-38518168-ZBQ at doses of 3, 10, and 30 mg/d compared with placebo in subjects with active RA despite concomitant MTX therapy.
|Study start date||2012-09-04|